• Katherine Giuliano, Teviah Sachs, Elizabeth Montgomery, Angela Guzzetta, Malcolm Brock, Timothy M Pawlik, Stephen C Yang, and Nita Ahuja.
• School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States.
• Thorac Cardiovasc Surg. 2016 Mar 1; 64 (2): 150-8.

BackgroundThe most common site of metastasis for soft tissue sarcomas (STSs) is the lung. In patients who are candidates for resection, metastasectomy improves survival. Debate remains, however, on approach and patient selection for surgery.MethodsWe retrospectively analyzed demographics, tumor characteristics, peri- and postoperative factors for 53 patients who underwent lung metastasectomy for STS from 1989 to 2013. Disease-free intervals (DFIs) and survival were determined. Kaplan-Meier estimates and log-rank test were used for comparison and survival analyses.ResultsMedian overall survival (diagnosis to death or last visit) was 59.9 months (IQR: 118.5), with mean follow-up of 85.3 months (SD: 69.5). Post-lung metastasectomy survival was 82.9%, 52.2%, 28.3%, and 13.3% at 1, 3, 5, and 10 years, respectively. Age at diagnosis of less than 50 years (p = 0.037), a low pathologic grade (p = 0.040), and a DFI until metastasis of greater than 13.5 months (p = 0.007) were significant predictors of improved survival.ConclusionPatients diagnosed at a younger age with low-grade tumors and those with a longer DFI prior to metastasis diagnosis gain the greatest survival advantage with surgery.Georg Thieme Verlag KG Stuttgart · New York.

41 keywords...

hide…